Stay up to date

News

back to overview
Proteomedix Agrees to Issue Labcorp Exclusive License for Proclarix® Blood Test to Detect Prostate Cancer

May 22, 2023

American Urology Association includes Proclarix in the 2023 guideline.

April 27, 2023

Proclarix included in the 2023 European Association of Urology Guidelines

April 25, 2023

Results published demonstrating accurate diagnosis of prostate cancer by combining Proclarix with magnetic resonance imaging.

March 9, 2023

Proteomedix receives IVDR certification for Proclarix.

October 18, 2022

Proteomedix announces grant of Chinese patent on Proclarix®.

September 8, 2022

Side by side evaluation of Proclarix® and the Prostate Health Index (phi) for the identification of clinically significant prostate cancer.

August 23, 2022

Proteomedix announces grant of U.S. patent on Proclarix®.

July 5, 2022

New results on Proclarix® resolving indeterminate Magnetic Resonance Imaging (MRI) for improved prostate cancer diagnosis will be presented at the 37th Annual EAU Congress in Amsterdam, NL.

June 29, 2022

The Biodiagnostica Montevergine Malzoni Network in Mercogliano will introduce Proclarix® into its laboratory routine

May 11, 2022

New clinical data published from Proclarix® together with Magnetic Resonance Imaging (MRI) for improved prostate cancer diagnosis.

March 10, 2022

Clinical data published of a novel serum biomarker quintet that improves disease prognosis in men with confirmed prostate cancer

November 18, 2021

Proteomedix presents at the annual congress of the Italian Society of Urology in Riccione and the Society of Urologists in Private Hospitals in Modena.

October 14, 2021

Proteomedix präsentiert sich an der Jahresversammlung der Schweizerischen Gesellschaft für Urologie in Interlaken.

September 23, 2021

Proteomedix and New Horizon Health Limited enter into a research and development partnership.

September 21, 2021

Proteomedix präsentiert sich am Jahreskongress der Deutschen Gesellschaft für Urologie in Stuttgart

September 7, 2021

New Spanish clinical data from Proclarix® together with Magnetic Resonance Imaging (MRI) for improved prostate cancer diagnosis will be presented at the 36th Annual European Urology Congress.

July 6, 2021

University of Naples Federico II is implementing and evaluating Proclarix® to make it available in Italy

May 4, 2021

Zhengzhou University Henan Cancer Hospital (ZUHCH) and Proteomedix enter into a cooperation to clinically validate biomarker tests and bioinformatics for prostate cancer diagnostics

January 14, 2021

Results published of PROPOSe, a real-life prospective study of Proclarix, a novel blood-based test to support challenging biopsy decision making in prostate cancer

January 7, 2021

Swiss Center for Laboratory Medicine St. Gallen presents data from Proclarix® at American Association for Clinical Chemistry (AACC) Annual Scientific Meeting

December 10, 2020

University Hospital Frankfurt MVZ GmbH, first laboratory offering Proclarix in Germany

December 2, 2020

Bestätigung der diagnostischen Leistungsfähigkeit des ersten Schweizer Tests zur Biopsie-Entscheidung in der Prostatakrebs-Diagnostik

October 27, 2020

Verbesserte Prostatakrebsdiagnostik – Ein Überblick im Magazin der Schweizerischen Union für Labormedizin

June 25, 2020

Proteomedix appoints Dr Maurizio Ballerini, MD as VP Market Development EMEA and Dr Helene Peyro Saint-Paul, MD as Medical Advisor

May 26, 2020

Analytical performance of Proclarix® verified

May 19, 2020

Proteomedix and Dynex® Technologies enter into strategic alliance to provide automated workflows for Proclarix®

May 12, 2020

Center for Laboratory Medicine St. Gallen is the first laboratory to offer Proclarix®

April 2, 2020

Proteomedix announces commercial launch of Proclarix® in Europe

February 26, 2020

New data from Proclarix together with Magnetic Resonance Imaging (MRI) for improved prostate cancer diagnosis to be showcased at American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium

February 11, 2020

Proteomedix appoints Helge Lubenow as new CEO

January 10, 2020

Proteomedix today announced the appointment of Prof. em. Dr. med. Thomas Cerny as new member of the Board of Directors.

April 10, 2019

New publication confirms that the use of ProteoMediX proprietary blood-based biomarkers improves clinically significant prostate cancer diagnosis

November 9, 2018

ProteoMediX Raises CHF 5.2 million in Financing Round

August 27, 2018

Novel Biomarker Test Avoids Biopsies by Accurately Predicting High-Grade Prostate Cancer

April 13, 2018

New publication describes the development and clinical testing of ProteoMediX’ immunoassays for prostate cancer diagnosis

August 3, 2017